Taro Pharmaceutical Industries Ltd. (TARO)
| Market Cap | 1.62B |
| Revenue (ttm) | 629.18M +9.8% |
| Net Income | 53.87M +111.7% |
| EPS | 1.43 +110.3% |
| Shares Out | 37.58M |
| PE Ratio | 30.05 |
| Forward PE | 9.81 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 242,109 |
| Open | 42.97 |
| Previous Close | 42.97 |
| Day's Range | 42.89 - 42.98 |
| 52-Week Range | 32.67 - 45.76 |
| Beta | 0.56 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 24, 2024 |
About TARO
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprising allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer,... [Read more]
Financial Performance
In 2023, TARO's revenue was $629.18 million, an increase of 9.81% compared to the previous year's $572.95 million. Earnings were $53.87 million, an increase of 111.70%.
Financial StatementsNews
Sun Pharma Completes Taro Merger
Combined entity is better positioned to compete in increasingly competitive generics industry MUMBAI, India and PRINCETON, N.J. , June 24, 2024 /PRNewswire/ -- Sun Pharmaceutical Industries Limited (R...
Taro Shareholders Approve Merger with Sun Pharma
MUMBAI, India and NEW YORK , May 23, 2024 /PRNewswire/ -- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/o...
Taro Provides Results for Year Ended March 31, 2024
HAWTHORNE, N.Y.--(BUSINESS WIRE)--TARO PROVIDES RESULTS FOR YEAR ENDED MARCH 31, 2024.
Taro to Release Full Year Results on May 20, 2024
HAWTHORNE, N.Y.--(BUSINESS WIRE)--TARO TO RELEASE FULL YEAR RESULTS ON MAY 20, 2024.
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Taro Shareholders Vote “FOR” Taro Sun Pharma Merger
NEW YORK--(BUSINESS WIRE)--Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Taro Shareholders Vote “FOR” Taro Sun Pharma Merger.
TARO PHARMACEUTICAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Taro Pharmaceutical Industries Ltd. - TARO
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Taro Pharmaceuti...
Taro Announces Extraordinary General Meeting and Ordinary Class Meeting of Shareholders for Approval of Merger with Sun Pharmaceutical Industries Ltd.
NEW YORK--(BUSINESS WIRE)--Taro Announces Extraordinary General Meeting and Ordinary Class Meeting of Shareholders for Approval of Merger with Sun Pharmaceutical Industries Ltd.
Krensavage Asset Management Remains Opposed to Sun's Predatory Bid for Taro
NEW YORK , Jan. 30, 2024 /PRNewswire/ -- Krensavage Asset Management today sent the following message to a special committee evaluating Sun Pharmaceutical Industries Ltd.'s bid for Taro Pharmaceutical...
Taro to Release Third Quarter Results on January 25, 2024
HAWTHORNE, N.Y.--(BUSINESS WIRE)--Taro to Release Third Quarter Results on January 25, 2024.
Taro Announces Merger Agreement with Sun Pharma
Agreed Price of US$43.00 per Share to Deliver 48% Premium to Unaffected Price on May 25, 2023 MUMBAI, India and NEW YORK , Jan. 17, 2024 /PRNewswire/ -- Sun Pharmaceutical Industries Limited (Reuters:...
Taro to Release Second Quarter Results on October 26, 2023
HAWTHORNE, N.Y.--(BUSINESS WIRE)--Taro to Release Second Quarter Results on October 26, 2023.
These Israeli pharmaceutical stocks are down in the wake of Hamas attack
Shares of Israeli pharmaceutical companies took a hit in premarket trades Monday after Hamas' attack on Israel.
Taro Provides Results for the Quarter Ended June 30, 2023
HAWTHORNE, N.Y.--(BUSINESS WIRE)--TARO PROVIDES RESULTS FOR THE QUARTER ENDED JUNE 30, 2023.
Taro to Release First Quarter Results on July 26, 2023
HAWTHORNE, N.Y.--(BUSINESS WIRE)--TARO TO RELEASE FIRST QUARTER RESULTS ON JULY 26, 2023.
Krensavage Asset Management Opposes Sun's Lowball Bid for Taro
NEW YORK , July 19, 2023 /PRNewswire/ -- As the largest minority shareholder1 of Taro Pharmaceutical Industries Ltd. (NYSE: TARO), Krensavage Asset Management LLC opposes Sun Pharmaceutical Industries...
Taro Provides Results for Year Ended March 31, 2023
HAWTHORNE, N.Y.--(BUSINESS WIRE)--Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and year ended March 31, 2023. Q...
Taro to Release Full Year Results on May 23, 2023
HAWTHORNE, N.Y.--(BUSINESS WIRE)--Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the year ended March 31, 2023, after the close of ...
Taro Provides Results for December 31, 2022
HAWTHORNE, N.Y.--(BUSINESS WIRE)--Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and nine months ended December...
Taro to Release Third Quarter Results on January 24, 2023
HAWTHORNE, N.Y.--(BUSINESS WIRE)--Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the third quarter ended December 31, 2022, after...
Taro to Release Second Quarter Results on October 27, 2022
HAWTHORNE, N.Y.
Taro Pharmaceuticals Inc. Issues Voluntary Type I Recall of Taro-Zoledronic Acid Injection, 5 mg/100 mL, 100 mL Vial Due to Particulate Matter Over Specified Requirements
BRAMPTON, Ontario--(BUSINESS WIRE)--TARO PHARMACEUTICALS INC. ISSUES VOLUNTARY TYPE I RECALL OF TARO-ZOLEDRONIC ACID INJECTION, 5 MG/100 ML, 100 ML VIAL
Taro Provides Results for the Quarter Ended June 30, 2022
HAWTHORNE, N.Y.--(BUSINESS WIRE)--TARO PROVIDES RESULTS FOR THE QUARTER ENDED JUNE 30, 2022
Taro Annual Report on Form 20-F Available For Fiscal Year Ended March 31, 2022
HAWTHORNE, N.Y.--(BUSINESS WIRE)--07-26-22 March 2022 Annual Report on Form 20-F